Profile data is unavailable for this security.
About the company
Dizal Pharmaceutical Co Ltd is a China-based company mainly engaged in the exploration, research, development and commercialization of biopharmaceuticals. The Company focuses on the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The Company's main drug product is Sunvozertinib, which is used for patients with advanced NSCLC who have had disease progression after previous platinum-containing chemotherapy or are intolerant to platinum-containing chemotherapy and have confirmed EGFR Exon20ins mutation. The Company's other candidate drugs in pipeline are Golidocitinib, DZD8586, DZD2269, DZD1516 and DZD6008. The Company mainly conducts its businesses in the domestic market and overseas markets.
- Revenue in CNY (TTM)607.75m
- Net income in CNY-867.44m
- Incorporated2017
- Employees852.00
- LocationDizal Pharmaceutical Co LtdChina (Shanghai) Pilot Free Trade ZoneBuilding 4, No. 199, 245 Liangjing RoadSHANGHAI 201203ChinaCHN
- Phone+86 2 161095757
- Fax+86 2 158387361
- Websitehttps://www.dizalpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| InventisBio Co Ltd | 180.53m | -116.28m | 13.55bn | 185.00 | -- | 8.14 | -- | 75.06 | -0.2012 | -0.2012 | 0.3122 | 2.88 | 0.0988 | -- | 1.03 | 975,824.70 | -6.36 | -32.89 | -6.76 | -35.22 | 99.41 | -- | -64.41 | -682.73 | -- | -- | 0.0127 | -- | -9.02 | 25.00 | 15.41 | -- | -3.97 | -- |
| Mabwell Shanghai Bioscience Co Ltd | 624.52m | -947.49m | 14.80bn | 1.36k | -- | 19.44 | -- | 23.69 | -2.37 | -2.37 | 1.56 | 1.90 | 0.1384 | 0.3458 | 14.57 | 441,048.00 | -21.06 | -29.90 | -36.19 | -36.18 | 88.72 | 85.56 | -152.14 | -1,188.68 | 0.8093 | -10.82 | 0.7353 | -- | 56.28 | 46.68 | 0.9031 | -- | 12.25 | -- |
| Sinocelltech Group Ltd | 1.89bn | -310.15m | 18.08bn | 2.28k | -- | -- | -- | 9.58 | -0.6964 | -0.6964 | 4.24 | -0.1083 | 0.5458 | 0.4325 | 3.04 | 828,989.10 | -8.37 | -22.66 | -29.60 | -48.25 | 93.51 | 95.52 | -15.33 | -42.96 | 0.5008 | -0.6753 | 1.02 | -- | 33.13 | 294.24 | 127.39 | -- | 23.95 | -- |
| BeBetter Med Inc | -100.00bn | -100.00bn | 19.60bn | 150.00 | -- | 91.01 | -- | -- | -- | -- | -- | 0.4785 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0116 | -- | -- | -- | 67.59 | -- | -- | -- |
| InnoCare Pharma Ltd | 1.43bn | -229.64m | 24.19bn | 1.15k | -- | 6.63 | -- | 16.95 | -0.1508 | -0.1508 | 0.8855 | 3.78 | 0.1504 | 1.70 | 3.74 | 1,245,225.00 | -2.52 | -6.41 | -2.87 | -7.45 | 86.97 | 86.07 | -16.78 | -71.71 | 6.44 | -- | 0.1996 | -- | 36.68 | 281.63 | 30.20 | -- | 3.42 | -- |
| Dizal Pharmaceutical Co Ltd | 607.75m | -867.44m | 25.36bn | 852.00 | -- | 17.41 | -- | 41.73 | -2.01 | -2.01 | 1.40 | 3.14 | 0.2644 | 0.8102 | 5.84 | 713,322.50 | -37.97 | -46.55 | -55.30 | -56.24 | 95.12 | 90.63 | -143.64 | -825.75 | 2.42 | -111.09 | 0.4239 | -- | 294.24 | 54.40 | 23.63 | -- | 58.33 | -- |
| Joinn Laboratories China Co Ltd | 1.67bn | 225.09m | 25.93bn | 2.65k | 109.60 | 3.44 | -- | 15.54 | 0.3405 | 0.3405 | 2.37 | 10.84 | 0.175 | 0.7843 | 6.03 | 629,011.80 | 2.36 | 6.60 | 2.72 | 7.92 | 24.63 | 41.87 | 13.47 | 25.98 | 3.06 | -- | 0.0039 | 23.59 | -15.07 | 25.85 | -81.34 | -16.89 | 16.27 | -19.46 |
| Wuhan Healthgen Biotechnology Corp | 23.39m | -160.81m | 26.70bn | 215.00 | -- | 53.73 | -- | 1,141.74 | -0.4498 | -0.4498 | 0.0654 | 1.39 | -- | -- | -- | 131,386.80 | -- | -- | -- | -- | 41.12 | -- | -687.60 | -- | 0.359 | -30.87 | 0.5497 | -- | 3.92 | -- | 19.04 | -- | -- | -- |
| Biocytogen Phrmutcls (Beijing) Co Ltd | 1.33bn | 249.94m | 30.15bn | 1.28k | 134.37 | 34.42 | 77.63 | 22.64 | 0.5593 | 0.5593 | 2.98 | 2.18 | -- | -- | -- | 1,215,939.00 | -- | -- | -- | -- | 76.56 | -- | 18.77 | -- | 1.11 | 14.77 | 0.5281 | -- | 36.76 | -- | 108.76 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Dizal Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
8.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Taikang Asset Management Co. Ltd.as of 20 Oct 2025 | 5.00m | 1.10% |
| Rosefinch Fund Management Co., Ltd.as of 20 Oct 2025 | 4.65m | 1.03% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2025 | 4.51m | 1.00% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 4.51m | 1.00% |
| Penghua Fund Management Co., Ltd.as of 20 Oct 2025 | 4.49m | 0.99% |
| Nuode Asset Management Co., Ltd.as of 20 Oct 2025 | 4.28m | 0.94% |
| Caitong Fund Management Co., Ltd.as of 20 Oct 2025 | 4.18m | 0.92% |
| Maxwealth Fund Management Co., Ltd.as of 30 Jun 2025 | 3.68m | 0.81% |
| JPMorgan Asset Management (Asia Pacific) Ltd.as of 31 Dec 2025 | 2.74m | 0.60% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 2.40m | 0.53% |
More ▼
Data from 30 Jun 2025 - 30 Sep 2025Source: FactSet Research Systems Inc.
